New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMK-677 (Ibutamoren) vs Orforglipron

MK-677 (Ibutamoren) vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
MK-677 (Ibutamoren)
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
24 hours
~12 hours (once-daily oral dosing)
Admin Route
Oral
Oral
Research
Typical Dose
10–25 mg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once daily
Once daily
Key Benefits
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With